Comparative Efficacy of Azithromycin and Cefixime in the Treatment of Acute Infectious Invasive Diarrhea in Children | CMAC

Comparative Efficacy of Azithromycin and Cefixime in the Treatment of Acute Infectious Invasive Diarrhea in Children

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(3):202-211

Section
Type
Journal article

Abstract

This paper describes a multicenter, randomized study to compare clinical and microbiological efficacy, and safety of azithromycin (Sumamed®, Teva) and cefixime (Suprax®, Gedeon-Richter) in the treatment of acute infectious invasive diarrhea in children. In most patients (85.4%), the etiology of acute invasive diarrhea was salmonellosis, presenting with fever and blood in stool. Clinical efficacy of azithromycin was 86.2% compared to 87.2% for cefixime, with the similar clinical resolution of signs and symptoms. Overall microbiological efficacy of azithromycin in children with acute infectious invasive diarrhea was significantly higher than that of cefixime (83.3% vs. 58.3%; p<0.001). Microbiological efficacy in the treatment of salmonellosis was 81.8% and 52.6% for azithromycin and cefixime, respectively. Both antimicrobial agents have demonstrated a favorable safety profile.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared